The removal of damaged material from within atherosclerotic plaques (“fatty streaks”) to restore cardiovascular health is a key component of SENS, now being developed for the clinic by SRF ally Underdog Pharmaceuticals. Exciting new preclinical results from another group using this strategy have recently been published in ACS Nano.
Defatting the Streaks
- By SRF
- August 12, 2020
- 10:08 am
The removal of damaged material from within atherosclerotic plaques ("fatty streaks") to restore cardiovascular health is a key component of SENS, now being developed for the clinic by SRF ally Underdog Pharmaceuticals. Exciting new preclinical results from another group using this strategy have recently been published in ACS Nano.
- By SRF
- August 12, 2020
- 10:08 am
Recent Posts:
Sponsor a Student
SRF August 14, 2023 7:17 pm
Set My Heart Free: Two AmyloSENS Therapies Targeting Cardiac Amyloid in Clinical Trials
Michael Rae August 2, 2023 12:49 am
The Grand Opening of Our New Facilities
SRF July 9, 2023 3:42 pm
From Parachutes to Jetpacks: Clearing Brain Beta-Amyloid with Donanemab or Lecanemab Works, Though More Must be Done
Michael Rae June 5, 2023 6:56 pm
Lights, Camera, Action on AI-Powered Drug Discovery
SRF May 3, 2023 6:09 pm
Announcing the Biomarkers of Aging Consortium
SRF March 10, 2023 12:56 pm
Action at the Governmental Level for Longevity
SRF March 10, 2023 12:30 pm
Scenes from the Lab
SRF March 8, 2023 5:16 pm
A Busy Spring in the Education Department
SRF March 8, 2023 4:22 pm
New Peer-Reviewed Paper from SENS Research Foundation: Iron Homeostasis as a Senolytic Target
SRF February 8, 2023 5:47 pm
Announcement: Amicable Settlement of Donor Dispute
SRF October 28, 2022 3:34 pm